Sakar Healthcare Limited

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUNPHARMA.BO has a market cap of 4.5T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUNPHARMA.BO trades at ₹1,905.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUNPHARMA.BO's P/E ratio is 41.32. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SAKAR.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SUNPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUNPHARMA.NS has a market cap of 4.5T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUNPHARMA.NS trades at ₹1,905.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUNPHARMA.NS's P/E ratio is 41.33. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SAKAR.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SUNPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while DIVISLAB.BO trades at ₹6,833.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas DIVISLAB.BO's P/E ratio is 72.66. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SAKAR.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check DIVISLAB.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while DIVISLAB.NS trades at ₹6,835.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas DIVISLAB.NS's P/E ratio is 72.61. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SAKAR.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check DIVISLAB.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while TORNTPHARM.BO trades at ₹4,394.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas TORNTPHARM.BO's P/E ratio is 69.66. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, SAKAR.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check TORNTPHARM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while TORNTPHARM.NS trades at ₹4,393.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas TORNTPHARM.NS's P/E ratio is 65.75. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, SAKAR.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check TORNTPHARM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while DRREDDY.BO trades at ₹1,331.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas DRREDDY.BO's P/E ratio is 19.71. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, SAKAR.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check DRREDDY.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while DRREDDY.NS trades at ₹1,331.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas DRREDDY.NS's P/E ratio is 26.54. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, SAKAR.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check DRREDDY.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while LUPIN.NS trades at ₹2,252.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas LUPIN.NS's P/E ratio is 19.53. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, SAKAR.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check LUPIN.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while LUPIN.BO trades at ₹2,253.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas LUPIN.BO's P/E ratio is 24.10. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, SAKAR.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check LUPIN.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while MANKIND.BO trades at ₹2,504.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas MANKIND.BO's P/E ratio is 58.11. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SAKAR.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check MANKIND.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while MANKIND.NS trades at ₹2,495.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas MANKIND.NS's P/E ratio is 58.07. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SAKAR.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check MANKIND.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ZYDUSLIFE.NS has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ZYDUSLIFE.NS trades at ₹991.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ZYDUSLIFE.NS's P/E ratio is 20.63. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ZYDUSLIFE.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ZYDUSLIFE.BO has a market cap of 1T. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ZYDUSLIFE.BO trades at ₹991.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ZYDUSLIFE.BO's P/E ratio is 20.59. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ZYDUSLIFE.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AUROPHARMA.NS has a market cap of 878.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AUROPHARMA.NS trades at ₹1,500.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AUROPHARMA.NS's P/E ratio is 25.21. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, SAKAR.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AUROPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AUROPHARMA.BO has a market cap of 877.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AUROPHARMA.BO trades at ₹1,501.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AUROPHARMA.BO's P/E ratio is 25.66. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, SAKAR.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AUROPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, LAURUSLABS.BO has a market cap of 715B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while LAURUSLABS.BO trades at ₹1,327.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas LAURUSLABS.BO's P/E ratio is 84.79. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check LAURUSLABS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, LAURUSLABS.NS has a market cap of 714.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while LAURUSLABS.NS trades at ₹1,329.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas LAURUSLABS.NS's P/E ratio is 84.74. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check LAURUSLABS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GLENMARK.NS has a market cap of 656.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GLENMARK.NS trades at ₹2,339.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GLENMARK.NS's P/E ratio is 61.73. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GLENMARK.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GLENMARK.BO has a market cap of 656.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GLENMARK.BO trades at ₹2,340.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GLENMARK.BO's P/E ratio is 61.70. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GLENMARK.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ALKEM.NS has a market cap of 655.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ALKEM.NS trades at ₹5,468.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ALKEM.NS's P/E ratio is 27.65. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ALKEM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ALKEM.BO has a market cap of 655.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ALKEM.BO trades at ₹5,457.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ALKEM.BO's P/E ratio is 27.70. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ALKEM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, SAKAR.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SUVENPHAR.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, SAKAR.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SUVENPHAR.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, IPCALAB.BO has a market cap of 407.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while IPCALAB.BO trades at ₹1,646.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas IPCALAB.BO's P/E ratio is 44.77. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check IPCALAB.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, IPCALAB.NS has a market cap of 407.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while IPCALAB.NS trades at ₹1,646.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas IPCALAB.NS's P/E ratio is 44.77. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check IPCALAB.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AJANTPHARM.NS has a market cap of 396.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AJANTPHARM.NS trades at ₹3,214.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AJANTPHARM.NS's P/E ratio is 37.64. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SAKAR.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AJANTPHARM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AJANTPHARM.BO has a market cap of 396.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AJANTPHARM.BO trades at ₹3,211.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AJANTPHARM.BO's P/E ratio is 39.14. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SAKAR.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AJANTPHARM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, JBCHEPHARM.NS has a market cap of 343.7B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while JBCHEPHARM.NS trades at ₹2,125.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas JBCHEPHARM.NS's P/E ratio is 48.21. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check JBCHEPHARM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, JBCHEPHARM.BO has a market cap of 343.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while JBCHEPHARM.BO trades at ₹2,124.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas JBCHEPHARM.BO's P/E ratio is 48.16. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check JBCHEPHARM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, EMCURE.NS has a market cap of 323.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while EMCURE.NS trades at ₹1,685.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas EMCURE.NS's P/E ratio is 34.97. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check EMCURE.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SAKAR.NS is more volatile compared to PEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check PEL.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, WOCKPHARMA.BO has a market cap of 251.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while WOCKPHARMA.BO trades at ₹1,572.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas WOCKPHARMA.BO's P/E ratio is 117.29. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, SAKAR.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check WOCKPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, WOCKPHARMA.NS has a market cap of 251.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while WOCKPHARMA.NS trades at ₹1,571.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas WOCKPHARMA.NS's P/E ratio is 117.56. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, SAKAR.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check WOCKPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, PPLPHARMA.BO has a market cap of 231.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while PPLPHARMA.BO trades at ₹175.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas PPLPHARMA.BO's P/E ratio is -71.12. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SAKAR.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check PPLPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, PPLPHARMA.NS has a market cap of 231.7B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while PPLPHARMA.NS trades at ₹175.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas PPLPHARMA.NS's P/E ratio is -71.09. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, SAKAR.NS is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check PPLPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NATCOPHARM.BO has a market cap of 215.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NATCOPHARM.BO trades at ₹1,167.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NATCOPHARM.BO's P/E ratio is 14.01. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NATCOPHARM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NATCOPHARM.NS has a market cap of 214.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NATCOPHARM.NS trades at ₹1,165.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NATCOPHARM.NS's P/E ratio is 13.78. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NATCOPHARM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NEULANDLAB.NS has a market cap of 212.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NEULANDLAB.NS trades at ₹16,327.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NEULANDLAB.NS's P/E ratio is 58.51. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, SAKAR.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NEULANDLAB.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NEULANDLAB.BO has a market cap of 212.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NEULANDLAB.BO trades at ₹16,328.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NEULANDLAB.BO's P/E ratio is 58.36. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, SAKAR.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NEULANDLAB.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ASTRAZEN.BO has a market cap of 212.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ASTRAZEN.BO trades at ₹8,530.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ASTRAZEN.BO's P/E ratio is 105.33. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, SAKAR.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ASTRAZEN.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ASTRAZEN.NS has a market cap of 211.7B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ASTRAZEN.NS trades at ₹8,513.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ASTRAZEN.NS's P/E ratio is 104.94. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, SAKAR.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ASTRAZEN.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ERIS.BO has a market cap of 190.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ERIS.BO trades at ₹1,340.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ERIS.BO's P/E ratio is 43.65. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, SAKAR.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ERIS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ERIS.NS has a market cap of 189.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ERIS.NS trades at ₹1,340.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ERIS.NS's P/E ratio is 43.52. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, SAKAR.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ERIS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GRANULES.NS has a market cap of 182.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GRANULES.NS trades at ₹731.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GRANULES.NS's P/E ratio is 30.05. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, SAKAR.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GRANULES.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GRANULES.BO has a market cap of 178.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GRANULES.BO trades at ₹731.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GRANULES.BO's P/E ratio is 32.66. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, SAKAR.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GRANULES.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, COHANCE.BO has a market cap of 162.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while COHANCE.BO trades at ₹429.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas COHANCE.BO's P/E ratio is 90.90. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check COHANCE.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, COHANCE.NS has a market cap of 161.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while COHANCE.NS trades at ₹428.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas COHANCE.NS's P/E ratio is 90.62. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check COHANCE.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, JUBLPHARMA.NS has a market cap of 156.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while JUBLPHARMA.NS trades at ₹1,009.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas JUBLPHARMA.NS's P/E ratio is 36.31. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, SAKAR.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check JUBLPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, JUBLPHARMA.BO has a market cap of 156.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while JUBLPHARMA.BO trades at ₹1,011.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas JUBLPHARMA.BO's P/E ratio is 36.15. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, SAKAR.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check JUBLPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, APLLTD.BO has a market cap of 154.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while APLLTD.BO trades at ₹723.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas APLLTD.BO's P/E ratio is 24.45. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check APLLTD.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, APLLTD.NS has a market cap of 154.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while APLLTD.NS trades at ₹724.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas APLLTD.NS's P/E ratio is 24.46. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check APLLTD.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, CAPLIPOINT.BO has a market cap of 151.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while CAPLIPOINT.BO trades at ₹1,987.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas CAPLIPOINT.BO's P/E ratio is 23.75. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check CAPLIPOINT.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, CAPLIPOINT.NS has a market cap of 151.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while CAPLIPOINT.NS trades at ₹1,986.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas CAPLIPOINT.NS's P/E ratio is 23.74. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check CAPLIPOINT.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GLS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, SAKAR.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GLS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ALIVUS.NS has a market cap of 128.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ALIVUS.NS trades at ₹1,055.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ALIVUS.NS's P/E ratio is 23.60. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ALIVUS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ALIVUS.BO has a market cap of 127B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ALIVUS.BO trades at ₹1,055.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ALIVUS.BO's P/E ratio is 23.41. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ALIVUS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SAKAR.NS is more volatile compared to CAPPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check CAPPL.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, STAR.BO has a market cap of 106.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while STAR.BO trades at ₹1,114.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas STAR.BO's P/E ratio is 20.82. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check STAR.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, STAR.NS has a market cap of 106.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while STAR.NS trades at ₹1,151.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas STAR.NS's P/E ratio is 20.79. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SAKAR.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check STAR.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, VIYASH.NS has a market cap of 98B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while VIYASH.NS trades at ₹225.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas VIYASH.NS's P/E ratio is 86.69. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, SAKAR.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check VIYASH.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SHILPAMED.NS has a market cap of 93.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SHILPAMED.NS trades at ₹476.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SHILPAMED.NS's P/E ratio is 42.26. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SHILPAMED.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, PGHL.NS has a market cap of 88B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while PGHL.NS trades at ₹5,255.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas PGHL.NS's P/E ratio is 37.26. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, SAKAR.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check PGHL.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, PGHL.BO has a market cap of 87.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while PGHL.BO trades at ₹5,261.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas PGHL.BO's P/E ratio is 37.13. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, SAKAR.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check PGHL.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AKUMS.NS has a market cap of 79.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AKUMS.NS trades at ₹520.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AKUMS.NS's P/E ratio is 30.99. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, SAKAR.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AKUMS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUDEEPPHRM.NS has a market cap of 73.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUDEEPPHRM.NS trades at ₹649.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUDEEPPHRM.NS's P/E ratio is 43.67. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, SAKAR.NS is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SUDEEPPHRM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AARTIPHARM.BO has a market cap of 64.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AARTIPHARM.BO trades at ₹708.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AARTIPHARM.BO's P/E ratio is 30.33. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, SAKAR.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AARTIPHARM.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AARTIPHARM.NS has a market cap of 64.5B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AARTIPHARM.NS trades at ₹701.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AARTIPHARM.NS's P/E ratio is 30.17. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, SAKAR.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AARTIPHARM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, FDC.NS has a market cap of 59.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while FDC.NS trades at ₹361.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas FDC.NS's P/E ratio is 27.51. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, SAKAR.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check FDC.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, FDC.BO has a market cap of 59.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while FDC.BO trades at ₹362.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas FDC.BO's P/E ratio is 27.43. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, SAKAR.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check FDC.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SPARC.NS has a market cap of 53.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SPARC.NS trades at ₹162.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SPARC.NS's P/E ratio is -19.88. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, SAKAR.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SPARC.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SPARC.BO has a market cap of 53.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SPARC.BO trades at ₹161.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SPARC.BO's P/E ratio is -19.83. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, SAKAR.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SPARC.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SEQUENT.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SEQUENT.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, INNOVACAP.NS has a market cap of 49.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while INNOVACAP.NS trades at ₹877.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas INNOVACAP.NS's P/E ratio is 34.79. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SAKAR.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check INNOVACAP.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUVEN.BO has a market cap of 49B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUVEN.BO trades at ₹253.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUVEN.BO's P/E ratio is -17.16. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, SAKAR.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check SUVEN.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SUVEN.NS has a market cap of 47.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SUVEN.NS trades at ₹252.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SUVEN.NS's P/E ratio is -17.15. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, SAKAR.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SAKAR.NS.Check SUVEN.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SHILPAMED.BO has a market cap of 46.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SHILPAMED.BO trades at ₹477.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SHILPAMED.BO's P/E ratio is 42.35. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, SAKAR.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SHILPAMED.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GUJTHEM.NS has a market cap of 40.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GUJTHEM.NS trades at ₹350.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GUJTHEM.NS's P/E ratio is 84.54. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, SAKAR.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GUJTHEM.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, RPGLIFE.BO has a market cap of 38B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while RPGLIFE.BO trades at ₹2,290.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas RPGLIFE.BO's P/E ratio is 18.75. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check RPGLIFE.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, RPGLIFE.NS has a market cap of 37.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while RPGLIFE.NS trades at ₹2,300.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas RPGLIFE.NS's P/E ratio is 18.72. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, SAKAR.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check RPGLIFE.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ORCHPHARMA.BO has a market cap of 36.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ORCHPHARMA.BO trades at ₹713.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ORCHPHARMA.BO's P/E ratio is 190.87. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SAKAR.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ORCHPHARMA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, ORCHPHARMA.NS has a market cap of 36.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while ORCHPHARMA.NS trades at ₹713.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas ORCHPHARMA.NS's P/E ratio is 190.53. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SAKAR.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check ORCHPHARMA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AARTIDRUGS.NS has a market cap of 33.6B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AARTIDRUGS.NS trades at ₹365.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AARTIDRUGS.NS's P/E ratio is 16.64. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, SAKAR.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AARTIDRUGS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, AARTIDRUGS.BO has a market cap of 33.5B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while AARTIDRUGS.BO trades at ₹365.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas AARTIDRUGS.BO's P/E ratio is 16.62. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, SAKAR.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check AARTIDRUGS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, IOLCP.NS has a market cap of 31.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while IOLCP.NS trades at ₹108.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas IOLCP.NS's P/E ratio is 26.82. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, SAKAR.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check IOLCP.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, IOLCP.BO has a market cap of 31.1B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while IOLCP.BO trades at ₹108.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas IOLCP.BO's P/E ratio is 26.82. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, SAKAR.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check IOLCP.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NOVARTIND.NS has a market cap of 29.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NOVARTIND.NS trades at ₹1,178.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NOVARTIND.NS's P/E ratio is 30.73. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NOVARTIND.NS's ROE of +0.13%. Regarding short-term risk, SAKAR.NS is more volatile compared to NOVARTIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NOVARTIND.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, NOVARTIND.BO has a market cap of 29.8B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while NOVARTIND.BO trades at ₹1,180.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas NOVARTIND.BO's P/E ratio is 30.70. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, SAKAR.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check NOVARTIND.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, BLISSGVS.BO has a market cap of 29.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while BLISSGVS.BO trades at ₹291.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas BLISSGVS.BO's P/E ratio is 27.30. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, SAKAR.NS is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check BLISSGVS.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, BLISSGVS.NS has a market cap of 29.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while BLISSGVS.NS trades at ₹287.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas BLISSGVS.NS's P/E ratio is 27.27. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, SAKAR.NS is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check BLISSGVS.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GUFICBIO.BO has a market cap of 28.4B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GUFICBIO.BO trades at ₹278.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GUFICBIO.BO's P/E ratio is 57.06. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, SAKAR.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GUFICBIO.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, GUFICBIO.NS has a market cap of 28.3B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while GUFICBIO.NS trades at ₹277.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas GUFICBIO.NS's P/E ratio is 56.63. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, SAKAR.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check GUFICBIO.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SOLARA.NS has a market cap of 27.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SOLARA.NS trades at ₹561.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SOLARA.NS's P/E ratio is -120.31. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, SAKAR.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SOLARA.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, SOLARA.BO has a market cap of 27.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while SOLARA.BO trades at ₹556.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas SOLARA.BO's P/E ratio is -120.22. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, SAKAR.NS is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check SOLARA.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, UNICHEMLAB.NS has a market cap of 26.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while UNICHEMLAB.NS trades at ₹374.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas UNICHEMLAB.NS's P/E ratio is 8.91. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check UNICHEMLAB.NS's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, UNICHEMLAB.BO has a market cap of 26.2B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while UNICHEMLAB.BO trades at ₹371.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas UNICHEMLAB.BO's P/E ratio is 8.90. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SAKAR.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check UNICHEMLAB.BO's competition here

SAKAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAKAR.NS stands at 15.3B. In comparison, HIKAL.BO has a market cap of 24.9B. Regarding current trading prices, SAKAR.NS is priced at ₹779.95, while HIKAL.BO trades at ₹196.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAKAR.NS currently has a P/E ratio of 61.11, whereas HIKAL.BO's P/E ratio is 252.25. In terms of profitability, SAKAR.NS's ROE is +0.10%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, SAKAR.NS is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SAKAR.NS.Check HIKAL.BO's competition here